Videos

The panel discusses which of the four approved combination regimens in advanced clear cell RCC they would choose for higher-risk patients, and the factors that play into the decision.

In the second installment of the series, Ben Creelan, MD, reviews clinical trial data and explains the rationale of using tumor-infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) treatment.

Alexey Danilov, MD, PhD, discusses the current treatment landscape for chronic lymphocytic leukemia and how it has evolved.

Amit M. Oza, MD, discusses progression-free survival findings from the phase 3 ARIEL4 clinical trial.

Raajit Rampal, MD, PhD, discusses unmet needs for therapies to treat patients with myelofibrosis.

Alonso Gutierrez, MD, discusses the initial results from a feasibility study which evaluated the use of a daily wearable patient-tracking device to optimize radiation machine use and time the delivery of treatment.

Charles J. Schneider, MD, FACP, discusses the next steps in managing and treating patients with anal carcinoma.

Dr Mark Socinski reviews the challenges faced when treating chemotherapy induced myelosuppression and discusses the impact of trilaciclib on CIM and how that will impact clinical practice.

Anna Jo Bodurtha Smith, MD, MPH, MSc, discusses how oncologists and health systems can overcome barriers to access to the best available care for patients with gynecologic cancers.

Aime T. Franco, PhD, provides an overview of her discussion regarding the molecular landscape of pediatric patients with thyroid cancer at the 91st Annual Meeting of the American Thyroid Association.

Dr Peter Martin discusses the impact of CAR-T cell therapy in patients with MCL and provides a brief review of key efficacy data from the ZUMA-2 trial.

Key opinion leaders describe the role of hypomethylating agents in treating higher-risk MDS and the treatment options after HMA failure.

Hetty Carraway, MD, illustrates the role of allogenic stem cell transplant in MDS and the criteria used to determine a patient’s eligibility.

Fred Saad, MD, FRSC, discusses the key biomarkers looked at in an analysis of the phase 3 PROpel trial analyzing olaparib plus abiraterone to treat patients with metastatic castration resistant prostate cancer.

Adam Cohen, MD, discusses when patients should receive chimeric antigen receptor T-cell therapies for relapsed/refractory multiple myeloma.

Manojkumar Bupathi, MD, MS, discusses the updated efficacy results of the CheckMate 9ER trial of cabozantinib plus nivolumab for patients with previously untreated advanced clear cell renal cell carcinoma.

Dr Scott Tykodi shares his take on discontinuation of IO-TKI combination regimens because of toxicities.

An expert explains how he assesses a patient’s tolerability of the IO-TKI combination regimens and at what point he discontinues treatment.

Glenn J. Hanna, MD, discusses the results of a study investigating nivolumab as treatment for proliferative leukoplakia leading to oral cancer.

Eytan M. Stein, MD, outlines the biggest factors to consider when choosing a treatment for higher-risk MDS, including the differences in quality-of-life for patients.

Dr Hetty Carraway reviews the available treatment options for patients with higher-risk MDS, and the biggest challenges of treatment.

Peter A. McSweeney, MD, discusses the challenges that come with administering chimeric antigen receptor T-cell therapy. He also explains how CAR T cells entering the second-line may change the ways community practices choose treatments for their patients.

Aaron Logan, MD, PhD, discusses some of the treatment options available for patients with acute lymphoblastic leukemia.

Bijal Shah, MD, MS, discusses the unmet medical needs in the T-cell acute lymphoblastic leukemia space and what future research aims to examine.

Rana McKay, MD, shares advice for community oncologists treating patients with advanced renal cell carcinoma.

Dr Rana McKay discusses the rationale for using cabozantinib with nivolumab and ipilimumab in the COSMIC 313 trial and reviews the adverse events seen with this combination in the COSMIC 313 trial.

Dr Rana McKay reviews key efficacy data from the COSMIC 313 trial and discusses factors that are considered when choosing between IO-TKI or IO-IO combinations.

Dr Rana McKay discusses the efficacy and qualify-of-life data from the 5-year follow-up of the CheckMate 214 trial investigating nivolumab plus ipilimumab in frontline advanced renal cell carcinoma treatment.

Rana McKay, MD, presents the case of a 73-year-old man with advanced renal cell carcinoma, shares her initial impression, and reviews which factors contribute to a patient’s risk status.

William J. Gradishar, MD, discusses the choice of adjuvant or neoadjuvant regimens for patients with HER2-positive breast cancer.